CYP2B6 Polymorphisms in Methadone Disposition

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes methadone.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Methadone

Criteria

Inclusion Criteria:

Each subject must meet all of the following criteria:

• 18-50 yr old

• CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype

• Good general health with no remarkable medical conditions

• BMI < 33

• Provided informed consent

Exclusion Criteria:

Subjects will not be enrolled if any of the following criteria exist:

• Known history of liver or kidney disease

• Use of prescription or non prescription medications, herbals or foods known to be metabolized by or affect CYP2B6

• Females who are pregnant or nursing

• Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)

• Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)